Compass Pathways reports six-month data from its second Phase III COMP006 trial of COMP360 psilocybin for treatment-resistant depression, showing 39% of patients achieved clinically meaningful response maintained through 26 weeks. NDA submission expected in Q4 2026.
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
Compass Pathways said COMP360 for treatment-resistant depression retains FDA Breakthrough Therapy designation as it advances in phase 3. A Trump executive order also directs faster federal review of psychedelic drugs with breakthrough status.
DEA and New York authorities seized over 8,800 counterfeit fentanyl pills and 891 grams of cocaine in Brooklyn, arresting one suspect. In a separate operation, agents recovered 20 pounds of methamphetamine and $50,000 in cash. The busts are part of efforts to disrupt synthetic drug shipments into New York City.
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
